

**ATTORNEY DOCKET NO. 14014.0312
PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of)

Kelsall et al.)

Serial No. 09/196,867)

Filed: November 20, 1998)

For: METHODS OF USING CR3 AND CR4)
LIGANDS FOR INHIBITING)
INTERLEUKIN-12 TO TREAT)
AUTOIMMUNE DISEASE)

Group Art Unit: 1644

Examiner: DeCloux, A.

RECEIVED

NOV 16 1999

GROUP 1800#8
B.G.J.
11/29/99**ELECTION UNDER RESTRICTION REQUIREMENT****VIA FACSIMILE TRANSMISSION****703/305-3704**

ATTN: Examiner A. DeCloux

Group Art Unit 1644

Assistant Commissioner for Patents

Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.

Suite 1200, The Candler Building

127 Peachtree Street, N.E.

Atlanta, Georgia 30303-1811

November 15, 1999

Sir:

This is in response to the Office Action dated September 17, 1999, wherein restriction of the claims of the above-identified application is required. The Office Action requires restriction to one of the following three groups of claims:

Group I: Claims 1-11, drawn to a method of downregulating IL-12 with CR3/4 ligands.

Group II: Claim 12, drawn to a method of screening a substance for its ability to downregulate IL-12 upon binding CR3.

Group III: Claim 13, drawn to a method of screening a substance for its ability to